Publications by authors named "Kurt Hertogs"

Claim this Profile
A
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies.
Mireille Pellis, Els Pardon, Kourosh Zolghadr, Ulrich Rothbauer, Cécile Vincke, Kurt Hertogs

Arch Biochem Biophys· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Olivia Goethals, Marcia Van Ginderen, Ann Vos, Maxwell D Cummings, Koen Van Der Borght, Kurt Hertogs

Antiviral Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Olivia Goethals, Ann Vos, Marcia Van Ginderen, Peggy Geluykens, Veerle Smits, Kurt Hertogs

Virology· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
Jérôme Guillemont, Abdellah Benjahad, Said Oumouch, Laurence Decrane, Patrice Palandjian, Kurt Hertogs

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Reginald Clayton, Asa Ohagen, Francois Nicol, Alfred M Del Vecchio, Tim H M Jonckers, Kurt Hertogs

Antiviral Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
Olivia Goethals, Reginald Clayton, Marcia Van Ginderen, Inge Vereycken, Elisabeth Wagemans, Kurt Hertogs

J Virol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout.
Edwin Gong, Tania Ivens, Christel Van den Eynde, Sabine Hallenberger, Kurt Hertogs

J Virol Methods· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
Inge Dierynck, Mieke De Wit, Emmanuel Gustin, Inge Keuleers, Johan Vandersmissen, Kurt Hertogs

J Virol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
Géry Dams, Koen Van Acker, Emmanuel Gustin, Inge Vereycken, Lieve Bunkens, Kurt Hertogs

J Biomol Screen· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
Céline Mordant, Benoit Schmitt, Elisabeth Pasquier, Christophe Demestre, Laurence Queguiner, Kurt Hertogs

Eur J Med Chem· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.
Reginald Clayton, Asa Ohagen, Olivia Goethals, Alexandra Smets, Marnix Van Loock, Kurt Hertogs

J Virol Methods· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.
Dirk Jochmans, Jérôme Deval, Bart Kesteleyn, Herwig Van Marck, Eva Bettens, Kurt Hertogs

J Virol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.
Marie-Pierre de Béthune, Kurt Hertogs

Curr Med Res Opin· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
Tania Ivens, Christel Van den Eynde, Koen Van Acker, Erik Nijs, Géry Dams, Kurt Hertogs

J Virol Methods· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Wim G Verschueren, Inge Dierynck, Katie I E Amssoms, Lili Hu, Paul M J G Boonants, Kurt Hertogs

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
Jerome Guillemont, Elisabeth Pasquier, Patrice Palandjian, Daniel Vernier, Sandrine Gaurrand, Kurt Hertogs

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
Africa Holguín, Ellen Paxinos, Kurt Hertogs, Chad Womac, Vincent Soriano

J Clin Virol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.
Scott A Wegner, Mark R Wallace, Naomi E Aronson, Sybil A Tasker, David L Blazes, Kurt Hertogs

Clin Infect Dis· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
Martin Stürmer, Schlomo Staszewski, Hans W Doerr, Kurt Hertogs

AIDS Res Hum Retroviruses· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
P Richard Harrigan, Kurt Hertogs, Werner Verbiest, Brendan Larder, Benita Yip

Antivir Ther· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.
A Gregory DiRienzo, Victor DeGruttola, Brendan Larder, Kurt Hertogs

Stat Med· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
Christian Eggers, Kurt Hertogs, Hans-Jörg Stürenburg, Jan van Lunzen, Hans-Jürgen Stellbrink

AIDS· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
Mark Dybul, Elizabeth Nies-Kraske, Marybeth Daucher, Kurt Hertogs, Claire W Hallahan

J Infect Dis· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.
Christiane Adjé-Touré, Bilé Celestin, Debra Hanson, Thierry H Roels, Kurt Hertogs

AIDS· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
Paul J Weidle, Robert Downing, Catherine Sozi, Raymond Mwebaze, Gideon Rukundo, Kurt Hertogs

AIDS· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis